Company profits from side effects of glaucoma treatment

Banaszek, Adrianna
October 2011
CMAJ: Canadian Medical Association Journal;10/4/2011, Vol. 183 Issue 14, pE1058
Academic Journal
The article reports on the willingness of a number of people to take the health risks associated with bimatoprost, used to treat glaucoma, which is marketed by Allergan Inc. to obtain longer eyelashes. Frederick Mikelberg, head of the ophthalmology department at the University of British Columbia, states that many are prepared to take those risks to achieve the cosmetic benefit of longer eyelashes. April Sanders, skin and vein care physician, mentions that the demand for the drug is growing.


Related Articles

  • SECTION 7: EYE DISORDERS.  // Monthly Prescribing Reference;Aug2011, Vol. 27 Issue 8, p143 

    The article offers information on several drugs used for treating various eye disorders including ocular infections, glaucoma, and dry eye. It says that Azasite from Inspire Pharmaceutical Inc. is used for treating ocular infection and is recommended for children aged 1-year-old and above. It...

  • Alpha agonist OK'd for glaucoma.  // Drug Topics;9/16/96, Vol. 140 Issue 18, p7 

    Reports on the Food and Drug Administration's approval for Allergan to market Alphagan (brimonide) for the treatment of open-angle glaucoma and ocular hypertension.

  • DERMATOLOGICAL DISORDERS: 5B Acne.  // MPR - Pharmacist's Edition;Fall2011, Vol. 5 Issue 3, p96 

    The article offers information on various drugs for the treatment of acne, as well as their precautions, interactions, and adverse reactions. It says that Aczone from Allergan Inc. is not recommended for children less than 12 years old. It mentions the adverse reactions of Amnesteem from Mylan...

  • MD formulations bought by MDF.  // Global Cosmetic Industry;Sep99, Vol. 165 Issue 3, p6 

    Reports that MDF Acquisition Corp. has acquired the M.D. Formulations and M.D. Forte skincare lines from Allergan Inc. Terms under the acquisition deal.

  • Allergan offers glaucoma advice. M.A. // Medical Marketing & Media;Jun2003, Vol. 38 Issue 6, p33 

    Reports on Allergan's offering of an educational campaign designed to raise awareness of glaucoma and, in turn, drive sales of its Lumigan and Alphagan glaucoma treatments. Joint effort between Allergan and Webb-Patterson Communications; Target market of the campaign.

  • Allergan chief receives award from glaucoma foundation. Webb, Jennifer A. // Ophthalmology Times;3/15/2006, Vol. 31 Issue 6, p6 

    The article reports on Allergan Inc. Chairman David E.I. Pyott's receipt of the Glaucoma Research Foundation Catalyst Award in recognition of his contributions to the prevention of glaucoma. Pyott anticipates the potential success of the memantine, a drug being studied in a glaucoma trial which...

  • EYE DISORDERS: 8B Glaucoma.  // MPR - Pharmacist's Edition;Fall2011, Vol. 5 Issue 3, p140 

    The article offers information on various drugs for treating eye disorders such as glaucoma. It says that Alphagan P from Allergan Inc. is for open-angle glaucoma, in which its adverse reactions include oral dryness, burning, and stinging. It states that Cosopt from Merck & Co. Inc. is a...

  • Bilateral Deepening of Upper Lid Sulcus From Topical Bimatoprost Therapy. Yam, Jason C. S.; Yuen, Nancy S. Y.; Chan, Clement W. N. // Journal of Ocular Pharmacology & Therapeutics;Oct2009, Vol. 25 Issue 5, p471 

    Purpose: To report a new adverse effect related to treatment with bimatoprost. Method: Case report. A 43-year-old Asian female with bilateral glaucoma was noticed to have bilateral deepening of upper lid sulcus 3 months after beginning treatment with bimatoprost 0.03%. Results: Bimatoprost was...

  • ALLERGIC DISORDERS.  // Monthly Prescribing Reference;Dec2014, Vol. 30 Issue 12, p1 

    The article offers information on several drugs for several allergic disorders, cardiovascular diseases, and dermatological disorders. Among the drugs discussed include Allegra from Chattem, Zyrtec from McNeil Consumer Healthcare, and Aczone from Allergan Inc. Information regarding...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics